AND-PD

Comorbidity Mechanisms of Anxiety and Parkinson's Disease

Providing new insights to advance personalised treatment of PD patients and open new research avenues supporting prevention, diagnosis and management of co-morbidities in PD patients

Parkinson's Disease (PD) is the neurodegeneration of pathways in the brain that are critical for action selection and movement control. Such pathways are also vital for the distribution of dopamine and serotonin, the neurotransmitters that control our mood. The disruption of information usually communicated by dopamine and serotonin are highly demonstrated as causative factors of anxiety in previous research.

The AND-PD project will investigate the impact of PD on such pathways in the brain to further understand the functional and pathological changes caused by the disease.

There are 10 work packages in the AND-PD project

1

Defining the phenotype of comorbid anxiety/depression in PD animal models  

2

 Defining the neural circuitry that underlies comorbidity 

3

Disruption of neural circuitry to cause co-morbidity

4

Rescue co-morbidities with novel RNA based neuroprotection and circuit interventions in the mid-brain that restore the functional role of specific neurons. 

5

Molecular characterisation of PD co-morbidities

6

Linking mid-brain degeneration with anxiety/depression symptoms in post-mortem PD brain samples 

7

Mid-brain functional connectivity in PD patients

8

Clinical phenotyping and risk factors of comorbidities in patients 

9

Dissemination and Exploitation 

10

Consortium Management and Governance 

  • LinkedIn
  • Twitter
  • YouTube